Last update Dec. 2, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
M01AB14 is Proglumetacin Maleate in ATC Code/s.Is written in other languages:
M01AB14 is also known as
M01AB14 belongs to this group or family:
|Tmax||5.46 ± 0.17||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Nonsteroidal anti-inflammatory drug (NSAID) derived from indomethacin-related indoleacetic acid. It is a pro-drug of indomethacin conjugated with proglumide, a gastric protector that inhibits gastric secretion by being an antagonist of cholecystokinin. It has been used in musculoskeletal and joint disorders. Oral, rectal and topical cream administration at 5%.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Although it has a high molecular weight that would hinder its excretion in breast milk, the absence of published pharmacokinetic data does not allow its excretion in breast milk to be predicted.
Product with very few and/or very old bibliographic references, marketed in few countries.
Safer known alternatives are preferable during breastfeeding, especially during the neonatal period and in case of prematurity.